Federal contract award

FA480321F0035

LAB REAGENTS ANALYZER ON A "COST-PER-TEST" BASIS.

Research the contractorView USAspending sourceSave to my pursuit research

Award details

Obligations, current value and potential value describe different measures; they are never added together.

FieldReported value
AgencyDepartment of Defense
OfficeFA4803 20 CONS LGCA
NAICS334516 — Analytical Laboratory Instrument Manufacturing
PSC6550 — In Vitro Diagnostic Substances, Reagents, Test Kits and Sets
Parent award / vehicleV797D60637
Set-asideNot reported
Pricing typeFIRM FIXED PRICE
Obligations$376.1K
Current contract value$486.5K
Potential contract value / ceiling$593.9K
Start dateJun 30, 2021
Current end dateJun 29, 2026
Potential end dateJun 29, 2026
Latest award activityMay 13, 2026
Source loadedSep 19, 2026

Funding and modification history

Showing the latest 9 of 9 loaded transactions. Negative values are deobligations.

DateModificationObligation changeDescription
May 13, 2026P00009$17.8KCLINICAL DRY SLIDE TECHNOLOGY CHEMISTRY AND IMMUNODIAGNOSTIC TESTING 5600 VITRO INTEGRATED SYSTEM ANALYZER.
Dec 22, 2025P00008$-41.2KCLINICAL DRY SLIDE TECHNOLOGY CHEMISTRY AND IMMUNODIAGNOSTIC TESTING 5600 VITRO INTEGRATED SYSTEM ANALYZER.
Nov 18, 2025P00007$0CLINICAL DRY SLIDE TECHNOLOGY CHEMISTRY AND IMMUNODIAGNOSTIC TESTING 5600 VITRO INTEGRATED SYSTEM ANALYZER.
Jan 30, 2025P00005$-35.7KCLINICAL DRY SLIDE TECHNOLOGY CHEMISTRY AND IMMUNODIAGNOSTIC TESTING 5600 VITRO INTEGRATED SYSTEM ANALYZER.
Sep 20, 2024P00004$0CLINICAL DRY SLIDE TECHNOLOGY CHEMISTRY AND IMMUNODIAGNOSTIC TESTING 5600 VITRO INTEGRATED SYSTEM ANALYZER.
Jun 20, 2024P00003$107.4KCLINICAL DRY SLIDE TECHNOLOGY CHEMISTRY AND IMMUNODIAGNOSTIC TESTING 5600 VITRO INTEGRATED SYSTEM ANALYZER.
Jun 14, 2023P00002$110.3KFA480321F0035- ORTHO CLINICAL REAGENTS
Apr 20, 2022P00001$110.3KEXERCISE OPTION YEAR 1 AND INCORPORATE ADDITIONAL TESTING.
Jun 25, 20210$107.4KLAB REAGENTS ANALYZER ON A "COST-PER-TEST" BASIS.

Research next steps

  1. Confirm the ordering vehicle and your eligibility or a qualified teaming route.
  2. Review the award scope and buyer evidence before making a bid/no-bid decision.